key: cord-0981728-q53dexbu
authors: Inal, Jameel
title: COVID‐19 comorbidities, associated pro‐coagulant extracellular vesicles and venous thromboembolisms: a possible link with ethnicity?
date: 2020-07-09
journal: Br J Haematol
DOI: 10.1111/bjh.17011
sha: ca9035fdccac1df8180d7cd64d1d8f5ff0aefb20
doc_id: 981728
cord_uid: q53dexbu

Several comorbidities predict mortality in patients with COVID‐19, some of which are more prevalent in Black Asian and Minority Ethnic (BAME) groups. Extracellular vesicles (EVs) released from cells are nano‐sized membrane‐bound vesicles that carry nucleic acids and proteins and mediate intercellular communication. In COVID‐19 associated comorbidities including diabetes, CVD and risk factors such as hypertension, elevated angiotensin II and obesity, levels of circulating EVs are raised and their cargo modified. Importantly, EVs released from damaged endothelial cells are known to be procoagulant. EVs in Black and White populations differentially express phosphorylated insulin signalling proteins, associated with impaired insulin signalling, insulin resistance and an increased risk of venous thromboembolism; these EV proteins are also associated with clinical mortality risk markers. If plasma EV levels are raised, and cargo modified in comorbidities associated with COVID‐19 such as diabetes, and account for excess deaths in BAME patients, this raises the possibility for important roles of EVs, also relating to ethnicity. This places EVs as hitherto understudied key factors, filling the current knowledge gap in COVID‐19, amongst BAME patients.

comorbidities including diabetes, CVD and risk factors such as hypertension, elevated angiotensin II (Ang II) and obesity, levels of circulating EVs are raised. [3] [4] [5] [6] Increased EVs, especially from injured or TNF-α-stimulated endothelial cells (EC) carrying tissue factor (TF + ), or from platelets exposing phosphatidylserine (PS + ), are known to be procoagulant and to cause VTE. 7 Levels of EVs also correlate with von Willebrand Factor (vWF), a marker of EC damage and dysfunction, 8 that is released through Ang II-mediated superoxide damage and hypoxia-mediated oxidative stress and further still by severe acute respiratory syndrome coronavirus (SARS-CoV-2) binding to angiotensin-converting enzyme 2 (ACE2) on ECs and ensuant complement-mediated inflammation, 9 ( Figure [A and B] ). Previously, EC-mEV levels were found to be associated with stroke 10 and more recently CD31 + and CD144 + EC-derived mEVs, phenotypes reflecting apoptosis and structurally damaged endothelium, were found to relate to risk factors for CVD and thus increased risk of VTE, especially raised triglycerides, hypertension and metabolic syndrome. 4 Could it therefore be that changes in circulating EVs, raised and with modulated cargo in certain comorbidity groups, and possibly still further by infection with SARS-CoV-2, renders COVID-19 patients particularly susceptible to VTE? If so, EVs could be used as biomarkers in COVID-19. A TF + -EV procoagulant activity assay for example, based on fibrin formation, previously used in monitoring the risk of VTE in cancer patients, should be tried in COVID-19.

It was recently reported that higher rates of death from COVID-19 in the U.K. were found in BAME patients. 11 This study calculated the risk of death, adjusted for age and region, compared to the general population, the Standardized Mortality Ratio (SMR). The adjusted ethnic-specific If plasma EV levels are raised, and cargo modified in comorbidities associated with COVID-19, such as diabetes, and accounting for excess deaths in BAME patients, could EVs be playing a role and might there be a connection to ethnicity? In the United States, African Americans (AA) show a disproportionately high comborbidity-associated death rate from COVID-19, compared to White Americans (WA). 13 Interestingly, in work looking firstly at concentration and mean/modal sizes of circulating plasma EVs in AA and WA, regardless of gender, no ethnic difference was found. 14 However, assessing EV protein content involved in insulin signalling, the work found lower levels of phospho-AKT (pAKT) in AAs compared to WA which is associated with impaired insulin signalling, insulin resistance and an increased risk of VTE. Importantly, considering phosphorylated insulin signalling proteins, shown previously by the same group to be in EVs, and related to diabetes mellitus, 2, 3 the association of these EV proteins with clinical mortality risk markers, such as serum creatinine, lactate dehydrogenase (LDH), homeostatic model assessment of β-cell function (HOMA-B), serum alkaline phosphatase (ALP) and pulse pressure, did seem to depend on ethnicity.

The connection between EV cargo, mortality markers and race, may be of considerable importance, due to the current knowledge gap in susceptibility for COVID-19 amongst BAME patients. We know that EVs play roles in T2D 3 and CVD 4 and may thus constitute important risk factors leading to VTE in COVID-19. It is already known that proteins such as vWF contributing to VTE, show an association with ethnicity. 15 However, given that certain EV proteins and their relationship with clinical mortality markers may also vary according to ethnicity (summarized in

This article is protected by copyright. All rights reserved C5b-9 ). The resulting Ca 2+ influx through deposited C5b-9 and by the SARS-CoV-2 E-protein Ca 2+ channel from ERGIC/ER, leads to Ca 2+mediated EV release. Circulating EVs carrying phosphorylated insulin signalling proteins and related to diabetes mellitus, an important comorbidity in COVID-19, are associated with clinical mortality risk markers linked to ethnicity, A and B. In severe COVID-19, in particular in ethnicities with increased comorbidities such as diabetes, A, and associated circulating EV levels, EVs with their known role in coagulopathy could play an important role in COVID-19-related deaths through VTE. 

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis

Altered Extracellular Vesicle Concentration, Cargo, and Function in Diabetes

Association of circulating endothelial microparticles with cardiometabolic risk factors in the Framingham Heart Study

Effects of severe hypertension on endothelial and platelet microparticles

Circulating procoagulant microparticles in obesity

Biology and Role of Extracellular Vesicles (EVs) in the Pathogenesis of Thrombosis

The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Translational research : the journal of laboratory and clinical medicine

Circulating endothelial microparticles in acute ischemic stroke: a link to severity, lesion volume and outcome

Asian and Minority Ethnic groups in England are at increased risk of death from COVID-19: indirect standardisation of NHS mortality data

The ISARIC CCP-UK Prospective Observational Cohort Study of Hospitalised Patients. The Lancet

Black-White Risk Differentials in COVID-19 (SARS-COV2) Transmission, Mortality and Case Fatality in the United States: Translational Epidemiologic Perspective and Challenges

Association of Extracellular Vesicle Protein Cargo with Race and Clinical Markers of Mortality

Plasma hemostatic factors and endothelial markers in four racial/ethnic groups: the MESA study

Accepted Article

The author confirms being the sole author of this letter.